What the Trials Measured on HRT and Libido

Systemic hormone therapy mostly does not move desire directly. Where it helps sexual function, the benefit sits in lubrication, pain and satisfaction, which is a different thing from wanting sex. At Longevity Benchmark, we separate what clinical trials and regulatory documents actually establish from marketing claims around hormone replacement therapy. One intervention does have an evidence-based desire indication: testosterone for postmenopausal hypoactive sexual desire disorder (HSDD). No formulation is approved for women in the United States, safety data stop at 24 months, and the average benefit is about one satisfying sexual event per month over placebo.

Menopausal Transition and Predictors of Sexual Function

Longitudinal cohort data demonstrate that the menopausal transition itself predicts only increased pain and decreased desire, leaving most dimensions of sexual function unchanged. In the Study of Women's Health Across the Nation (SWAN), researchers monitored 3,302 women aged 42 to 52 at baseline across six annual follow-ups. After adjusting for baseline age, chronological aging, and social, health, and psychological factors, the odds of reporting vaginal or pelvic pain increased and desire decreased by late perimenopause. However, the menopausal transition was unrelated to the other six measured outcomes, which included importance of sex, sexual arousal, frequency of sexual intercourse, emotional satisfaction with partner, and physical pleasure.

Non-hormonal variables accounted for the vast majority of variation in sexual well-being across the study period. In the SWAN analysis, general health, psychological functioning, and the baseline importance of sex predicted every sexual function domain, whereas the menopausal transition predicted only two. Changes in relationship dynamics, chronic medical conditions, and psychological stress exert a wider influence across sexual function domains than reproductive endocrine shifts alone.

Population-level survey data confirm that low sexual desire becomes a clinical concern only when accompanied by personal distress. In the United States PRESIDE survey of 31,581 women aged 18 and older, the age-adjusted prevalence of any sexual problem was 43.1%, and sexually-related personal distress was reported by 22.2%. However, the prevalence of a distressing sexual problem was only 12.0%, peaking at 14.8% in women aged 45 to 64 compared to 10.8% in younger cohorts and 8.9% in older women. Clinical distress, defined as a Female Sexual Distress Scale score of 15 or greater, separated an incidental complaint from a disorder requiring treatment. Correlates of distressing problems included depression, anxiety, poor self-assessed health, thyroid conditions, and urinary incontinence.

Clinical Trial Endpoints and Measurement Instruments

Clinical trials evaluate female sexual function through standardized scoring instruments that separate subjective interest from counted events and personal distress. The most widely cited instrument is the Female Sexual Function Index (FSFI), developed in 131 healthy controls and 128 women with female sexual arousal disorder. The FSFI evaluates six distinct domains: desire, subjective arousal, lubrication, orgasm, satisfaction, and pain. Psychometric validation demonstrates high test-retest reliability (r = 0.79 to 0.86) and strong internal consistency, with Cronbach's alpha values at or above 0.82 across domains.

The FSFI Desire domain, used as a primary endpoint in pharmaceutical trials, is calculated from a narrow question set. As documented in the prescribing information for Addyi and Vyleesi, the desire score is built from two questions that assess desire frequency and intensity. Those two items are summed and multiplied by 0.6, generating a score range of 1.2 to 6.0. Because the score range is compressed, a treatment effect that appears small as a raw number can represent a measurable shift on the instrument.

Personal distress and physical activity are evaluated using distinct recall periods and behavioral metrics. Distress is commonly tracked using Item 13 of the Female Sexual Distress Scale-Revised (FSDS-R), which asks how often a patient was bothered by low sexual desire on a scale from 0 (never) to 4 (always). Addyi trials evaluated this distress metric over a 7-day recall window, whereas Vyleesi trials used a 30-day recall window, meaning the two headline distress numbers are not directly comparable. Satisfying sexual events (SSEs) are recorded via daily diary questions evaluating whether an event occurred and whether it was satisfying. The Addyi label explicitly defines an event as sexual intercourse, oral sex, masturbation, or genital stimulation by a partner, confirming that endpoint counts are not restricted to intercourse.

Systemic Estrogen Therapy and Sexual Desire

Systemic hormone replacement therapy does not reliably improve low sexual desire in postmenopausal women. In a comprehensive 2023 Cochrane review evaluating 36 studies and 23,299 women, estrogen alone versus control yielded a composite sexual-function standardized mean difference (SMD) of 0.50 (95% CI 0.04 to 0.96; I2 = 88%; 3 studies, 699 women) in symptomatic or early postmenopausal women. Across all nine studies reporting composite scores, the pooled SMD was 0.60 (95% CI 0.16 to 1.04; I2 = 92%; 1,307 women). However, in unselected postmenopausal women, estrogen alone yielded an SMD of 0.64 (95% CI -0.12 to 1.41; I2 = 94%; 6 studies, 608 women). Because the confidence interval crosses zero, the Cochrane authors concluded that systemic estrogen probably makes little or no difference in unselected postmenopausal populations.

The randomized evidence for combined estrogen-progestogen therapy is limited and shows no clear efficacy for sexual function. In the same 2023 Cochrane review, combined estrogen plus progestogen versus placebo in unselected postmenopausal women showed a mean difference of 0.08 (95% CI -1.52 to 1.68) based on a single study of 104 women, graded as very low-quality evidence. Synthetic steroids and receptor modulators showed similar limitations: Cochrane researchers graded evidence for tibolone and selective estrogen receptor modulators (SERMs) as very low quality, concluding that current trial data do not support a beneficial effect of tibolone or SERMs alone or combined with estrogen on sexual function.

Researchers within the Cochrane collaboration have reached conflicting conclusions across review editions. The 2013 version of the review evaluated estrogen alone in unselected postmenopausal women and found an SMD of 0.16 (95% CI -0.02 to 0.34, P = 0.08), concluding that benefit was absent in unselected women. The 2023 update analyzed a broader trial set and concluded that estrogen alone probably slightly improves scores in unselected women. Despite this shift in conclusions, both editions emphasized that the underlying trials carried high risk of bias, that only 7 of 36 studies designated sexual function as a primary outcome, and that observed benefits were concentrated in the lubrication, pain, and satisfaction domains rather than desire.

Clinical practice guidelines mirror these trial findings. The Menopause Society designates as Level I evidence in its 2022 position statement that systemic hormone therapy generally does not improve sexual function, sexual interest, arousal, or orgasmic response independent of its effect on genitourinary syndrome of menopause. For women seeking symptom relief who have libido concerns, the society notes as Level II evidence that transdermal estrogen may be preferable over oral administration, because transdermal therapy avoids the hepatic first-pass effect, minimizing increases in sex hormone-binding globulin (SHBG) and preserving circulating free testosterone. A trial enrolling only women diagnosed with sexual dysfunction, measuring desire as its primary outcome, would change this reading. The 2023 Cochrane authors note that no included trial did either.

Genitourinary Syndrome of Menopause and Local Therapies

Local vaginal treatments reduce dyspareunia by reversing tissue atrophy, but clinical trials show substantial placebo effects and conflicting statistical models. The 2020 GSM Position Statement notes that genitourinary syndrome of menopause affects between 27% and 84% of postmenopausal women, causing vaginal dryness, painful intercourse, burning, and dysuria. While first-line clinical guidance recommends over-the-counter non-hormonal lubricants and long-acting vaginal moisturizers for mild discomfort, the position statement acknowledges that few clinical trials have rigorously evaluated their efficacy.

A systematic review of local vaginal therapies found symptom relief alongside methodological limitations the reviewers graded as serious. In a 2016 Cochrane review of 30 randomized controlled trials encompassing 6,235 women, vaginal estrogen preparations outperformed placebo. Vaginal rings showed an odds ratio (OR) of 12.67 (95% CI 3.23 to 49.66; 1 RCT, n = 67), while creams demonstrated an OR of 4.10 (95% CI 1.88 to 8.93; 2 RCTs, n = 198). The review authors rated all pooled findings as low-quality evidence due to poor reporting of study methods and serious imprecision.

Disagreements also emerge within statistical modeling choices on the same local estrogen data. In the 2016 Cochrane review, vaginal estrogen tablets versus placebo yielded an OR of 12.47 (95% CI 9.81 to 15.84) under a fixed-effect statistical model, but yielded an OR of 5.80 (95% CI 0.88 to 38.29) under a random-effects model with high heterogeneity (I2 = 83%) across two trials totaling 1,638 women. The result was statistically significant under one statistical model and non-significant under the other. When comparing active delivery mechanisms directly, Cochrane researchers found no evidence of a difference in efficacy between rings, creams, and tablets.

Other prescription options for dyspareunia demonstrate modest clinical separation from placebo. Intravaginal prasterone (dehydroepiandrosterone, or DHEA), approved under the brand name Intrarosa for moderate to severe dyspareunia, reduced pain severity by 1.27 on a 0 to 3 scale over 12 weeks, compared to a reduction of 0.87 in the placebo group (difference of -0.40; P = 0.0132). The placebo response accounted for roughly two-thirds of the total reported improvement. Ospemifene, an oral selective estrogen receptor agonist/antagonist approved as Osphena, carries a boxed warning for endometrial cancer and cardiovascular disorders, with label-reported stroke rates of 1.13 for thromboembolic stroke and 3.39 for hemorrhagic stroke per 1,000 women-years.

Regulatory warnings for local therapies remain in transition across manufacturers. On 10 November 2025, the FDA announced it would remove the boxed warning from low-dose vaginal estrogen formulations. The Menopause Society commented that the historical boxed warning served as an unnecessary deterrent to safe and effective local treatment, while noting that systemic therapy still carries individual risks. However, specific product labels, such as the Vagifem estradiol vaginal insert label in the FDA database, have historically carried the class boxed warning, and label revisions across individual manufacturers do not take effect simultaneously.

Testosterone for Women and Measured Effect Sizes

Testosterone therapy is supported by clinical consensus exclusively for postmenopausal hypoactive sexual desire disorder, but no female formulation is approved by the Food and Drug Administration. The Global Consensus Position Statement on the Use of Testosterone Therapy for Women, endorsed by eleven international societies, states that HSDD is the only evidence-based indication for testosterone in women. The consensus document quantifies the expected clinical benefit as an average increase over placebo of one satisfying sexual event per month.

Endocrine testing cannot determine whether a patient is a candidate for testosterone therapy or predict clinical success. The Global Consensus statement notes that total testosterone blood levels should not be used to diagnose HSDD, and that no circulating androgen cutoff differentiates women with sexual dysfunction from those without. In clinical trials, baseline androgen concentrations did not predict treatment responsiveness.

The quantitative evidence base for postmenopausal testosterone was established in a systematic review and meta-analysis published by Islam and colleagues in The Lancet Diabetes & Endocrinology. Analyzing 36 randomized controlled trials and 8,480 participants, the researchers identified statistically significant improvements across multiple sexual domains, alongside small standardized effect sizes for desire, arousal, and orgasm.

Long-term safety data are limited, and regulatory guidance explicitly restricts recommended formulations. The Global Consensus statement highlights that safety data for physiological testosterone in women do not extend beyond 24 months of treatment. Compounded bioidentical testosterone cannot be recommended due to absent efficacy and safety documentation, and preparations producing supraphysiological levels, including subcutaneous pellets and intramuscular injections, are advised against. The Endocrine Society clinical practice guideline advises against diagnosing androgen deficiency syndrome in healthy women and recommends against testosterone use for cognition, bone density, cardiovascular health, or general well-being. The Endocrine Society's 2014 guideline accepts short-term efficacy and safety for postmenopausal HSDD and rejects every other indication. The 2019 Global Consensus is more permissive for HSDD specifically. The two disagree on breadth, not on direction.

The regulatory status of testosterone for women in the United States remains unresolved. Because no FDA-approved female testosterone drug exists, clinicians using testosterone adapt government-approved transdermal male formulations off-label at reduced female dosages, as outlined in clinical guidance from the International Society for the Study of Women's Sexual Health (ISSWSH). On 17 September 2026, the FDA convened a public meeting recorded under FDA docket FDA-2025-N-2589 to evaluate off-label use and critical evidence gaps regarding cardiovascular and breast cancer risks. In Europe, a transdermal testosterone patch (Intrinsa) delivering 300 micrograms daily was authorized in 2006 for surgically menopausal women receiving concomitant estrogen, but its marketing authorization was withdrawn in 2012 following notification by the manufacturer, as detailed in the European Medicines Agency Intrinsa record.

Professional societies disagree on whether testosterone should ever be considered before natural menopause. The 2019 Global Consensus concluded that data are insufficient to make any clinical recommendations regarding testosterone use in premenopausal women for sexual function or any other outcome. In contrast, the 2021 ISSWSH practice guideline stated that limited trial data support cautious testosterone prescribing in late reproductive age premenopausal women with HSDD.

Dose Response and Safety in the APHRODITE Trial

The largest clinical trial of transdermal testosterone in postmenopausal women demonstrated that sexual response depends on dose while highlighting unresolved breast safety questions. The APHRODITE study, published in The New England Journal of Medicine, evaluated 814 postmenopausal women diagnosed with HSDD who were not receiving concurrent estrogen therapy across a 52-week double-blind, placebo-controlled protocol.

Clinical efficacy differed between the tested patch strengths. At 24 weeks, women assigned to the 300 microgram per day transdermal patch experienced an increase of 2.1 satisfying sexual episodes over a 4-week period compared to an increase of 0.7 episodes on placebo (P < 0.001). In contrast, the lower 150 microgram per day patch resulted in an increase of 1.2 episodes, which was not statistically significantly different from placebo (P = 0.11). The lower dose failed to establish efficacy.

Androgenic side effects and clinical safety signals occurred during the 52-week monitoring phase. Unwanted facial and body hair growth occurred in 30.0% of women in the 300 microgram group compared to 23.1% in the placebo group. Over the study year, breast cancer was diagnosed in four women receiving testosterone compared to zero in the placebo arm. One cancer was diagnosed within the first four months of treatment, and another patient had breast symptoms that predated trial randomization. The trial investigators concluded that transdermal testosterone produced modest but meaningful improvements, while emphasizing that long-term safety, particularly regarding breast tissue, requires further investigation.

Non-Hormonal Prescription Medications for Low Desire

Non-hormonal medications approved for low sexual desire produce small questionnaire score changes alongside substantial placebo responses and high discontinuation rates. Flibanserin, an oral post-synaptic 5-HT1A agonist and 5-HT2A antagonist approved as Addyi, received initial FDA approval in August 2015. On 13 December 2025, according to the Drugs@FDA Addyi approval history, the FDA approved supplement 13 expanding the indication to women under 65 years of age with acquired, generalized HSDD, removing the previous premenopausal restriction.

Addyi carries a boxed warning for severe hypotension and syncope under specific clinical conditions. Prescribing information directs clinicians to instruct patients to wait at least two hours after consuming one or two standard alcoholic drinks before taking Addyi at bedtime, or to skip the dose entirely if three or more drinks were consumed that evening. Concomitant administration of moderate or strong CYP3A4 inhibitors and hepatic impairment are contraindicated. Dosing is strictly at bedtime to reduce the incidence of hypotension, syncope, and central nervous system depression, and the label instructs clinicians to discontinue therapy if no improvement is reported after eight weeks.

Pivotal clinical trials for Addyi revealed narrow treatment differences over placebo and failed co-primary endpoints. In Table 6 of the FDA label, the treatment difference in monthly satisfying sexual events versus placebo was 0.9 (95% CI 0.3 to 1.4) in Study 1, 0.6 (95% CI -0.03 to 1.2) in Study 2, and 1.0 (95% CI 0.4 to 1.5) in Study 3. The confidence interval in Study 2 crossed zero. Placebo arms improved by 0.8 to 1.5 events per month. The co-primary electronic diary sexual desire endpoint failed to reach statistical significance in both Study 1 (treatment difference 2.3; 95% CI -0.1 to 4.7) and Study 2 (treatment difference 1.7; 95% CI -0.5 to 4.0). On the FSFI Desire scale (1.2 to 6.0), the treatment difference was 0.3 to 0.4 points. In an independent meta-analysis of 5,914 women published in JAMA Internal Medicine, researchers found a pooled mean difference of 0.49 satisfying events per month (95% CI 0.32 to 0.67), alongside a twofold increased risk of discontinuation due to adverse events (RR 2.19; 95% CI 1.50 to 3.20).

Bremelanotide, a melanocortin receptor agonist approved as Vyleesi, presents a different clinical profile marked by behavioral null results. As detailed in the RECONNECT phase 3 trials, Vyleesi was approved in June 2019 as a self-administered subcutaneous autoinjector used at least 45 minutes before anticipated sexual activity, with a label statement that more than eight doses per month is not recommended. The product carries no boxed warning but is contraindicated in uncontrolled hypertension and cardiovascular disease, and its label restricts use to premenopausal women. The Vyleesi label explicitly notes a null result for behavioral events: there was no significant difference between treatment groups in the change from baseline in satisfying sexual events. Premature trial discontinuation due to adverse events reached 39% to 40% on drug compared to 13% to 25% on placebo, driven primarily by nausea, flushing, and headache.

Confounding Factors and Surgical Menopause Differences

Diminished libido during menopause is strongly predicted by mood disorders and sleep fragmentation rather than declining hormone concentrations alone. In baseline data from the Herbal Alternatives for Menopause Trial published in the American Journal of Obstetrics and Gynecology, researchers assessed 341 peri- and postmenopausal women aged 45 to 55 experiencing frequent hot flashes or night sweats who were not receiving hormone therapy. Diminished libido was present in 64% of participants, moderate to severe depression in 18%, and poor sleep quality in 43%.

Multivariate regression modeling clarified which symptoms drove low desire. Depressive symptoms (P = 0.003), poor sleep quality (P = 0.02), and nighttime sweats (P = 0.04) were each independently associated with diminished libido. In contrast, daytime hot flashes were not significantly associated with reduced desire.

Surgical removal of the ovaries creates an endocrine profile distinct from natural menopausal aging. The Menopause Society notes in its 2022 statement that bilateral oophorectomy results in an abrupt and persistent loss of ovarian testosterone production that does not occur in natural menopause. Because surgical menopause involves sudden concurrent estrogen and androgen depletion, clinical trial results from surgically menopausal cohorts do not translate directly to women transitioning through natural menopause.

Diagnostic Disagreements and Clinical Trial Limitations

Conflicting diagnostic criteria and short trial durations make treatment results for low sexual desire hard to compare across studies. The American Psychiatric Association's DSM-5 eliminated the diagnosis of hypoactive sexual desire disorder in women in 2013, combining desire and arousal into Female Sexual Interest/Arousal Disorder (FSIAD). In contrast, the World Health Organization's ICD-11 and the International Society for the Study of Women's Sexual Health retained HSDD as a standalone clinical diagnosis. Because clinical trials, diagnostic coding systems, and clinical guidelines do not evaluate a uniform condition, trial outcomes cannot be applied interchangeably across clinical settings.

Structural evidence gaps affect both hormonal and non-hormonal sexual health interventions. In the 2023 Cochrane review of systemic hormone therapy, not a single included randomized trial enrolled exclusively women diagnosed with sexual dysfunction. Safety data for physiological testosterone in women do not extend beyond 24 months of treatment, and trials were required to evaluate patients for only 12 weeks. Furthermore, endometrial safety data for local therapies such as vaginal estrogen, vaginal DHEA, and ospemifene have not been evaluated in clinical trials past one year, and safety in women with a history of breast cancer remains unconfirmed.

Federal regulatory authorities have underscored these evidence limitations. At the FDA public meeting on 17 September 2026, agency officials highlighted knowledge gaps regarding testosterone's long-term cardiovascular and breast cancer risks, the interpretation of female androgen biomarkers, and the absence of evidence for non-sexual outcomes such as cognition and musculoskeletal health. A medical evaluation is what separates local tissue discomfort from generalized low desire, and it is where concurrent sleep disruption and mood symptoms get weighed.

Related

• Testosterone Therapy for Women
• Estrogen Therapy Benefits
• HRT Side Effects and Risks
• Perimenopause Symptoms
• Stages of Menopause
• PT-141 evidence: what the bremelanotide label covers, and who its Limitations of Use exclude